glp-1 obesity drug news today oct 2025 Poll: 1 in 8 Adults Say They Are Currently Taking a for Weight Loss, Diabetes or Another Condition, Even as Half Say the Drugs Are Difficult to Afford GLP-1 trends 2025: real-world data,
Description
Shiraishi, D
Real-world data cited in the paper suggest roughly half of patients discontinue treatment within a year of starting it a rate far higher than the trials, with their closer supervision, capture
The project was headed up Nancy Thornberry, a biologist, and Ann Weber, a chemist (figure 34)
367 Specifically, liraglutide, both alone and in combination with insulin, effectively suppressed the formation of osteoclasts
Challenges regarding GLP-1 agonists include anti-fibrosis, long-term tolerability, and regaining weight
